E Osei1, S Fonville2, A A M Zandbergen3, P J Koudstaal3, D W J Dippel3, H M den Hertog4. 1. Medical Spectrum Twente, Enschede, The Netherlands. e.osei@mst.nl. 2. University Medical Center Utrecht, Utrecht, The Netherlands. 3. Erasmus Medical Center, Rotterdam, The Netherlands. 4. Medical Spectrum Twente, Enschede, The Netherlands.
Abstract
OBJECTIVES: Hyperglycemia on admission and diabetes mellitus type II are associated with unfavorable outcome in stroke patients. We studied whether impaired fasting glucose (IFG) is associated with unfavorable outcome in ischemic stroke patients treated with intravenous alteplase as well and if IFG is a stronger prognostic factor than hyperglycemia on admission. METHODS: We studied 220 consecutive patients with ischemic stroke treated with intravenous alteplase. In all nondiabetic patients, fasting glucose was determined on day 2-5. IFG was defined as fasting glucose level of ≥ 5.6 mmol/L, hyperglycemia on admission as glucose levels ≥ 7.9 mmol/L. The primary effect measure was the adjusted common odds ratio (acOR) for a shift in the direction of worse outcome on the modified Rankin Scale at 3 months, estimated with ordinal logistic regression, and adjusted for common prognostic factors. RESULTS: The fasting glucose levels were available in 194 and admission glucose levels in 215 patients. Sixty-three (32.5%) had IFG, 58 (27%) hyperglycemia on admission and 32 (14.6%) pre-existent diabetes. Patients with IFG showed a shift towards worse functional outcome compared with patients with normal fasting glucose levels (acOR 2.77; 95% CI 1.54-4.97), which was stronger than hyperglycemia on admission (acOR 1.75; 95% CI 0.91-3.4). CONCLUSIONS: IFG is associated with unfavorable outcome after treatment with intravenous alteplase for acute ischemic stroke. IFG predicts unfavorable outcome better than hyperglycemia on admission.
OBJECTIVES:Hyperglycemia on admission and diabetes mellitus type II are associated with unfavorable outcome in strokepatients. We studied whether impaired fasting glucose (IFG) is associated with unfavorable outcome in ischemic strokepatients treated with intravenous alteplase as well and if IFG is a stronger prognostic factor than hyperglycemia on admission. METHODS: We studied 220 consecutive patients with ischemic stroke treated with intravenous alteplase. In all nondiabetic patients, fasting glucose was determined on day 2-5. IFG was defined as fasting glucose level of ≥ 5.6 mmol/L, hyperglycemia on admission as glucose levels ≥ 7.9 mmol/L. The primary effect measure was the adjusted common odds ratio (acOR) for a shift in the direction of worse outcome on the modified Rankin Scale at 3 months, estimated with ordinal logistic regression, and adjusted for common prognostic factors. RESULTS: The fasting glucose levels were available in 194 and admission glucose levels in 215 patients. Sixty-three (32.5%) had IFG, 58 (27%) hyperglycemia on admission and 32 (14.6%) pre-existent diabetes. Patients with IFG showed a shift towards worse functional outcome compared with patients with normal fasting glucose levels (acOR 2.77; 95% CI 1.54-4.97), which was stronger than hyperglycemia on admission (acOR 1.75; 95% CI 0.91-3.4). CONCLUSIONS: IFG is associated with unfavorable outcome after treatment with intravenous alteplase for acute ischemic stroke. IFG predicts unfavorable outcome better than hyperglycemia on admission.
Authors: Nicholas L Smith; Joshua I Barzilay; Douglas Shaffer; Peter J Savage; Susan R Heckbert; Lewis H Kuller; Richard A Kronmal; Helaine E Resnick; Bruce M Psaty Journal: Arch Intern Med Date: 2002-01-28
Authors: Daniel M Kerr; Rachael L Fulton; Peter Higgins; Philip M W Bath; Ashfaq Shuaib; Patrick Lyden; Kennedy R Lees Journal: Stroke Date: 2011-11-10 Impact factor: 7.914
Authors: A Zangerle; S Kiechl; M Spiegel; M Furtner; M Knoflach; P Werner; A Mair; G Wille; C Schmidauer; K Gautsch; T Gotwald; S Felber; W Poewe; J Willeit Journal: Neurology Date: 2007-01-02 Impact factor: 9.910
Authors: José Alvarez-Sabín; Carlos A Molina; Joan Montaner; Juan F Arenillas; Rafael Huertas; Marc Ribo; Agusti Codina; Manuel Quintana Journal: Stroke Date: 2003-04-03 Impact factor: 7.914
Authors: A Bruno; S R Levine; M R Frankel; T G Brott; Y Lin; B C Tilley; P D Lyden; J P Broderick; T G Kwiatkowski; S E Fineberg Journal: Neurology Date: 2002-09-10 Impact factor: 9.910
Authors: Andrea Rocco; Peter U Heuschmann; Peter D Schellinger; Martin Köhrmann; Jennifer Diedler; Marek Sykora; Christian H Nolte; Peter Ringleb; Werner Hacke; Eric Jüttler Journal: Stroke Date: 2013-05-28 Impact factor: 7.914
Authors: Kotryna Genceviciute; Martina B Göldlin; Christoph C Kurmann; Adnan Mujanovic; Thomas R Meinel; Johannes Kaesmacher; David J Seiffge; Simon Jung; Pasquale Mordasini; Urs Fischer; Jan Gralla; Hakan Sarikaya; Barbara Goeggel Simonetti; Kateryna Antonenko; Roza M Umarova; Lia Bally; Marcel Arnold; Mirjam R Heldner Journal: Eur J Neurol Date: 2022-07-01 Impact factor: 6.288
Authors: Catherine M Davis; Wenri H Zhang; Elyse M Allen; Thierno M Bah; Robert E Shangraw; Nabil J Alkayed Journal: Int J Mol Sci Date: 2021-05-21 Impact factor: 5.923